Chimerix, Inc. (CMRX): Price and Financial Metrics

Chimerix, Inc. (CMRX): $1.01

0.02 (+2.02%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

Add CMRX to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#93 of 363

in industry

CMRX Price/Volume Stats

Current price $1.01 52-week high $1.57
Prev. close $0.99 52-week low $0.88
Day low $0.99 Volume 286,700
Day high $1.04 Avg. volume 425,648
50-day MA $1.05 Dividend yield N/A
200-day MA $1.05 Market Cap 90.10M

CMRX Stock Price Chart Interactive Chart >

CMRX POWR Grades

  • CMRX scores best on the Sentiment dimension, with a Sentiment rank ahead of 74.64% of US stocks.
  • CMRX's strongest trending metric is Value; it's been moving down over the last 26 weeks.
  • CMRX ranks lowest in Momentum; there it ranks in the 10th percentile.

CMRX Stock Summary

  • For CMRX, its debt to operating expenses ratio is greater than that reported by just 5.59% of US equities we're observing.
  • With a price/sales ratio of 74.15, CHIMERIX INC has a higher such ratio than 97.26% of stocks in our set.
  • Revenue growth over the past 12 months for CHIMERIX INC comes in at -96.57%, a number that bests merely 0.99% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to CHIMERIX INC are CCCC, AEVA, ACRS, FATE, and ANAB.
  • Visit CMRX's SEC page to see the company's official filings. To visit the company's web site, go to www.chimerix.com.

CMRX Valuation Summary

  • CMRX's price/sales ratio is 75.5; this is 1697.62% higher than that of the median Healthcare stock.
  • CMRX's price/sales ratio has moved up 62.6 over the prior 130 months.

Below are key valuation metrics over time for CMRX.

Stock Date P/S P/B P/E EV/EBIT
CMRX 2023-12-29 75.5 0.4 -1 -0.9
CMRX 2023-12-28 71.9 0.4 -1 -0.8
CMRX 2023-12-27 74.3 0.4 -1 -0.8
CMRX 2023-12-26 73.9 0.4 -1 -0.8
CMRX 2023-12-22 73.0 0.4 -1 -0.8
CMRX 2023-12-21 72.1 0.4 -1 -0.8

CMRX Growth Metrics

    The 3 year net income to common stockholders growth rate now stands at -49.37%.
  • Its 4 year net cashflow from operations growth rate is now at -43.98%.
  • The 3 year price growth rate now stands at -42.16%.
Over the past 49 months, CMRX's revenue has gone up $28,860,000.

The table below shows CMRX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 33.056 -60.902 153.629
2022-06-30 0.608 -83.318 -106.293
2022-03-31 0.559 -85.481 -100.588
2021-12-31 1.979 -99.93 -173.236
2021-09-30 3.053 -74.952 -145.413
2021-06-30 4.555 -67.963 -138.264

CMRX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CMRX has a Quality Grade of C, ranking ahead of 50.17% of graded US stocks.
  • CMRX's asset turnover comes in at 0.038 -- ranking 340th of 682 Pharmaceutical Products stocks.
  • CDXC, NAII, and PLX are the stocks whose asset turnover ratios are most correlated with CMRX.

The table below shows CMRX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.038 1 -1.745
2021-03-31 0.051 1 -2.103
2020-12-31 0.055 1 -0.855
2020-09-30 0.104 1 -0.533
2020-06-30 0.100 1 -1.270
2020-03-31 0.088 1 -1.075

CMRX Price Target

For more insight on analysts targets of CMRX, see our CMRX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $17.67 Average Broker Recommendation 1.33 (Strong Buy)

Chimerix, Inc. (CMRX) Company Bio


Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing novel, oral antivirals in areas of high unmet medical need. The company was founded in 2000 and is based in Durham, North Carolina.


CMRX Latest News Stream


Event/Time News Detail
Loading, please wait...

CMRX Latest Social Stream


Loading social stream, please wait...

View Full CMRX Social Stream

Latest CMRX News From Around the Web

Below are the latest news stories about CHIMERIX INC that investors may wish to consider to help them evaluate CMRX as an investment opportunity.

Positive Signs As Multiple Insiders Buy Chimerix Stock

Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...

Yahoo | December 14, 2023

Chimerix Promotes Michelle LaSpaluto to Chief Financial Officer

Proven Leader Brings More Than 25 Years of Financial ExperienceDURHAM, N.C., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the promotion of Michelle LaSpaluto, Vice President of Corporate Financial Planning and Investor Relations, to Chief Financial Officer effective December 1, 2023. “We are excited to announce this well

Yahoo | December 4, 2023

Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DURHAM, N.C., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on November 20, 2023, the Compensation Committee of Chimerix’s Board of Directors granted an inducement award to a new employee of non-qualified stock options to purchase 150,000 shares of Chimerix’s common stock. The Compensation Committee of Chimerix’s Board of Directors approved the award as an inducement material to the new employee’s employment agreement in accordance with Nasdaq Listing rule 5635(c

Yahoo | November 24, 2023

Chimerix Strengthens Executive Leadership Team with Appointment of Thomas Riga as Chief Operating and Commercial Officer

Seasoned Executive Brings More Than 25 Years of Industry Leadership Experience in Oncology Commercialization and Corporate Business DevelopmentDURHAM, N.C., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the appointment of Thomas Riga as Chief Operating and Commercial Officer. “We are excited to welcome Tom to the Chimerix

Yahoo | November 16, 2023

Chimerix, Inc. (NASDAQ:CMRX) Q3 2023 Earnings Call Transcript

Chimerix, Inc. (NASDAQ:CMRX) Q3 2023 Earnings Call Transcript November 2, 2023 Chimerix, Inc. misses on earnings expectations. Reported EPS is $-0.27 EPS, expectations were $-0.22. Operator: Good morning, ladies and gentlemen, and welcome to the Chimerix Third Quarter 2023 Earnings Conference Call. I would now like to introduce you to your host for today’s call, […]

Yahoo | November 3, 2023

Read More 'CMRX' Stories Here

CMRX Price Returns

1-mo -16.18%
3-mo 4.94%
6-mo 5.23%
1-year -18.55%
3-year -88.24%
5-year -51.90%
YTD 4.94%
2023 -48.25%
2022 -71.07%
2021 33.13%
2020 137.93%
2019 -21.01%

Continue Researching CMRX

Here are a few links from around the web to help you further your research on Chimerix Inc's stock as an investment opportunity:

Chimerix Inc (CMRX) Stock Price | Nasdaq
Chimerix Inc (CMRX) Stock Quote, History and News - Yahoo Finance
Chimerix Inc (CMRX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!